Bristol-Myers Squibb vs Hyundai: Founders, CEOs and History
Bristol-Myers Squibb was founded in 1887 by Edward Robinson Squibb, William McLaren Bristol, John Ripley Myers and is led by Christopher Boerner. Hyundai was founded in 1967 by Chung Ju-yung and is led by Jose Munoz.
Company facts
Bristol-Myers Squibb
- Founded
- 1887
- Headquarters
- Princeton, New Jersey
- Current CEO
- Christopher Boerner
- Employees
- 32,500
Hyundai
- Founded
- 1967
- Headquarters
- Seoul, South Korea
- Current CEO
- Jose Munoz
- Employees
- 123,000
Founders
Bristol-Myers Squibb
Edward Robinson Squibb
Squibb resigned his Navy post and opened a small laboratory in Brooklyn in 1858 to make pure ether, chloroform and other medicines.
William McLaren Bristol
In 1887 Bristol and Myers bought the Clinton Pharmaceutical Company of Clinton, New York, reportedly for about $5,000.
John Ripley Myers
Myers and Bristol bought the Clinton Pharmaceutical Company in Clinton, New York, in 1887 and renamed it Bristol, Myers and Company in 1898.
Hyundai
Chung Ju-yung
Chung Ju-yung was a South Korean industrialist and the founder of the Hyundai group. He left the poor farming village where he grew up and in 1947 started a small civil engineering company.
CEOs and their tenures
Bristol-Myers Squibb
- Charles A. Heimbold Jr.1994–2001
Chief Executive Officer
Serving as CEO from 1994 to 2001, he aggressively expanded the company's oncology portfolio, notably launching the blockbuster cancer drug Taxol, which drove massive revenue growth.
Source - Peter R. Dolan2001–2006
Chief Executive Officer
Dolan, who had run the consumer products and medical device divisions, succeeded Charles Heimbold in May 2001. His tenure included the ImClone partnership on the cancer drug Erbitux and a federal investigation into wholesaler inventory practices.
Source - James M. Cornelius2006–2010
Chief Executive Officer
Cornelius took over after Peter Dolan's removal in September 2006 and ran the company until May 2010.
Source - Lamberto Andreotti2010–2015
Chief Executive Officer
Andreotti, previously president and chief operating officer, became CEO on May 4, 2010.
Source - Giovanni Caforio2015–2023
Chief Executive Officer
Caforio, a physician, succeeded Lamberto Andreotti in May 2015. He led the $74 billion Celgene acquisition in 2019, the $13.1 billion MyoKardia deal in 2020 and the $4.1 billion Turning Point deal in 2022, and agreed the Mirati purchase in October 2023.
Source - Chris Boerner2023–present
Board Chair and Chief Executive Officer
Boerner became CEO in November 2023 and board chair on April 1, 2024, after serving as executive vice president, chief operating officer and CEO-designate from April 2023 and earlier as chief commercialization officer.
Source
Hyundai
- Chung Eui-sun2019–present
Executive Chair, Hyundai Motor Group (former co-CEO of Hyundai Motor)
He successfully elevated Hyundai and Kia from budget alternatives into highly desirable, premium-leaning brands, capturing significant global EV market share.
Source - Jaehoon Chang2021–2024
President and Chief Executive Officer
As co-CEO, he drove record-breaking operating profits in 2023 by prioritizing high-margin SUVs and luxury Genesis models amid global supply chain shortages.
Source - Jose Munoz2025–present
President and Chief Executive Officer
Munoz ran Hyundai's North American business and served as global COO before becoming CEO. Since 2025 he has led the response to U.S. tariffs, the $26 billion U.S. investment plan through 2028, the hybrid expansion and the 2030 target of 5.55 million sales.
Source
Timeline: Bristol-Myers Squibb and Hyundai side by side
1858Bristol-Myers Squibb
Edward Robinson Squibb opens his Brooklyn laboratory
Navy surgeon Edward Robinson Squibb started making pure ether and other medicines in Brooklyn. The laboratory burned down on Christmas Eve 1858 and reopened in 1859 after local doctors and surgeons contributed $2,100.
1887Bristol-Myers Squibb
Bristol and Myers buy the Clinton Pharmaceutical Company
Hamilton College graduates William McLaren Bristol and John Ripley Myers bought the Clinton Pharmaceutical Company of Clinton, New York, the business that became Bristol-Myers.
1898Bristol-Myers Squibb
Bristol, Myers and Company is named
The founders renamed the business Bristol, Myers and Company in May 1898. After Myers died in 1899 it became Bristol-Myers, which built national brands in Sal Hepatica and, from 1901, Ipana toothpaste.
1944Bristol-Myers Squibb
Penicillin at wartime scale
Squibb opened what was then the world's largest penicillin plant in New Brunswick, New Jersey. Bristol-Myers had bought Cheplin Biological Laboratories in East Syracuse, New York, in 1943 and converted it to penicillin for Allied forces.
1967Hyundai
Hyundai Motor Company Founded
Chung Ju-yung established Hyundai Motor Company, creating the automotive arm that would become the flagship of South Korea's car industry.
1975Hyundai
Hyundai Pony
The Hyundai Pony became Korea's first mass-produced passenger car and gave Hyundai a domestic platform for exports and engineering learning.
1986Hyundai
U.S. Market Entry
Hyundai entered the U.S. market with the Excel, rapidly building awareness as a value-oriented global automaker.
1989Bristol-Myers Squibb
Bristol-Myers and Squibb merge
Bristol-Myers and Squibb combined to form Bristol-Myers Squibb, uniting a consumer and pharmaceutical company with a research-led drugmaker.
1998Hyundai
Kia Stake Acquired
Hyundai acquired a controlling stake in Kia during the Asian financial crisis, creating the basis for Hyundai Motor Group's modern platform scale.
2006Bristol-Myers Squibb
CEO Peter Dolan removed over the Plavix deal
After an FBI raid in July 2006 over a patent settlement with generic maker Apotex on the blood thinner Plavix, the federal monitor urged the board to remove CEO Peter Dolan, who stepped down on September 12, 2006.
2009Bristol-Myers Squibb
Medarex bought and Mead Johnson split off
BMS bought Medarex, gaining Yervoy and a share of what became Opdivo, and split off Mead Johnson Nutrition in an exchange offer, completing its shift to a specialty biopharmaceutical company.
2011Bristol-Myers Squibb
FDA approves Yervoy
Yervoy (ipilimumab) became the first drug shown to extend overall survival in advanced melanoma, opening BMS's immuno-oncology franchise.
2012Bristol-Myers Squibb
FDA approves Eliquis
The FDA approved Eliquis (apixaban), developed with Pfizer, in December 2012 for stroke prevention in non-valvular atrial fibrillation. It became BMS's largest product, with $14.4 billion of sales in 2025.
2014Bristol-Myers Squibb
FDA approves Opdivo
The FDA approved the PD-1 inhibitor Opdivo (nivolumab) in December 2014 for advanced melanoma. It reached $10.0 billion of sales in 2025.
2015Hyundai
Genesis Luxury Brand
Hyundai launched Genesis as a standalone luxury brand, supporting premiumization and higher-margin global growth.
2019Bristol-Myers Squibb
Celgene acquisition closes
BMS completed its $74 billion purchase of Celgene on November 20, 2019, adding Revlimid, Pomalyst, Reblozyl and CAR-T programs. Celgene sold Otezla to Amgen for $13.4 billion to win regulatory approval.
2020Bristol-Myers Squibb
MyoKardia deal and a GAAP loss
BMS bought MyoKardia for $13.1 billion, gaining mavacamten (Camzyos). The deal's $11.4 billion in-process R&D charge pushed 2020 to a net loss despite $42.5 billion of revenue.
2020Hyundai
E-GMP EV Platform
Hyundai introduced its dedicated E-GMP electric-vehicle platform, giving models such as Ioniq 5 and Ioniq 6 fast-charging and packaging advantages.
2021Hyundai
Boston Dynamics Acquisition
Hyundai Motor Group acquired a controlling stake in Boston Dynamics, adding robotics to its long-term mobility and automation strategy.
2022Bristol-Myers Squibb
Turning Point bought as Revlimid generics arrive
BMS completed the $4.1 billion purchase of Turning Point Therapeutics in August 2022 while volume-limited generic lenalidomide began eroding Revlimid, which had peaked at $12.8 billion in 2021.
2023Bristol-Myers Squibb
Chris Boerner becomes CEO
Chris Boerner succeeded Giovanni Caforio as chief executive in November 2023 and became board chair on April 1, 2024. Weeks earlier BMS had agreed to buy Mirati, and in December it agreed to buy Karuna and RayzeBio.
2024Bristol-Myers Squibb
Karuna, Mirati and RayzeBio close; Cobenfy approved
The three deals closed between January and March 2024. On September 26, 2024 the FDA approved Cobenfy, the first schizophrenia drug that targets muscarinic rather than dopamine receptors. The Karuna charge produced an $8.9 billion net loss for 2024.
2025Bristol-Myers Squibb
BioNTech partnership, Orbital deal and $48.2B revenue
BMS agreed in June 2025 to co-develop BioNTech's bispecific BNT327 and in October 2025 to buy Orbital Therapeutics for $1.5 billion. Full-year revenue was $48.2 billion with the Growth Portfolio up 17 percent.
2025Hyundai
Jose Munoz Becomes CEO
Jose Munoz, previously Hyundai's global COO and head of its North American business, became President and CEO effective January 1, 2025, succeeding Jaehoon Chang. He is the first non-Korean to lead the company.
2025Hyundai
Record Revenue, Tariff-Hit Profit
Hyundai reported FY2025 revenue of ~$132 billion (KRW 186.25 trillion), up 6.3%, while operating profit fell 19.5% to ~$8.14 billion (KRW 11.47 trillion) and net profit fell 21.7% to ~$7.36 billion (KRW 10.36 trillion), largely due to U.S. tariffs.
2025Hyundai
Georgia Battery Plant Raid
In September 2025, U.S. immigration agents detained hundreds of workers, many of them Korean, at the Hyundai-LG Energy Solution battery plant under construction in Georgia, delaying its opening by months.
2026Bristol-Myers Squibb
Guidance raised and merger reports denied
On July 30, 2026 BMS raised its 2026 revenue guidance to $49.0 to $50.0 billion after second-quarter revenue of $12.97 billion. In August, reports of AstraZeneca merger talks were followed by a senior source telling Reuters there were no discussions.
2026Hyundai
Full Ownership of Boston Dynamics
In July 2026 Hyundai Motor Group moved to buy SoftBank's remaining stake in Boston Dynamics, a deal reported at about $325 million, making the robotics company wholly owned.
2026Hyundai
2026 CEO Investor Day
At its August 2026 CEO Investor Day, Hyundai reaffirmed a 2030 target of 5.55 million global sales and detailed its $26 billion U.S. investment plan through 2028.
Acquisitions
Bristol-Myers Squibb
- Orbital Therapeutics2025$1.5B
- Mirati Therapeutics2024$4.8B
- RayzeBio2024$4.1B
- Karuna Therapeutics2024$14B
- Turning Point Therapeutics2022$4.1B
- MyoKardia2020$13.1B
Questions about Bristol-Myers Squibb vs Hyundai
Who is the CEO of Bristol-Myers Squibb Company and Hyundai Motor Company?
Bristol-Myers Squibb Company is led by Christopher Boerner and Hyundai Motor Company is led by Jose Munoz. Both serve as the top executive responsible for the company's strategy, operations, and financial performance.
When was Bristol-Myers Squibb Company founded vs Hyundai Motor Company?
Bristol-Myers Squibb Company was founded in 1887 — 80 years before Hyundai Motor Company, which was founded in 1967. Bristol-Myers Squibb Company's longer operating history gives it a deeper track record but also potentially more institutional inertia compared to the younger Hyundai Motor Company.
How many employees does Bristol-Myers Squibb Company have compared to Hyundai Motor Company?
Bristol-Myers Squibb Company employs approximately 32,500 people, while Hyundai Motor Company employs approximately 123,000. Hyundai Motor Company has the larger workforce at 123,000 employees, compared to Bristol-Myers Squibb Company's 32,500. A higher headcount does not necessarily imply greater efficiency — it often reflects differences in business model (e.g., manufacturing vs. software).
Where are Bristol-Myers Squibb Company and Hyundai Motor Company headquartered?
Bristol-Myers Squibb Company is headquartered in United States and Hyundai Motor Company is headquartered in South Korea. Their different home markets mean they may face different regulatory frameworks, tax regimes, and currency exposure.
Who founded Bristol-Myers Squibb Company and Hyundai Motor Company?
Bristol-Myers Squibb Company was founded by Edward Robinson Squibb, William McLaren Bristol, John Ripley Myers. Hyundai Motor Company was founded by Chung Ju-yung.
Which company has a longer operating history — Bristol-Myers Squibb Company or Hyundai Motor Company?
Bristol-Myers Squibb Company has been operating for approximately 139 years, making it the more established of the two companies. Hyundai Motor Company has been in operation for around 59 years. A longer operating history often signals greater institutional resilience and brand recognition, though it can also mean slower adaptation to new market conditions.
Figures come from each company's filings and the sources linked beside them. Amounts reported in another currency are shown in US dollars at an approximate rate and marked with ~. Back to the Bristol-Myers Squibb vs Hyundai overview